SAN DIEGO, June 18 /PRNewswire/ - Sophisticated Infrastructure and Skilled Manpower Support Cutting-Edge Manufacturing Activities Singapore has firmly established itself as a leading manufacturing hub in Asia with its strong track record, sophisticated infrastructure, superior IP protection and reliability.
AbbVie Announces 223 Million Investment For New Biologics Manufacturing Facility In Singapore pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network.
Pharma firms eye Singapore for bigger global footprint--China Economic Net en.ce.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from en.ce.cn Daily Mail and Mail on Sunday newspapers.
Pharma firms eye Singapore for bigger global footprint chinadaily.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chinadaily.com.cn Daily Mail and Mail on Sunday newspapers.